In 1991, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as "Mindray") was established in Shenzhen. At that time, China's medical equipment market could be said to be almost the world of foreign brands. Therefore, at the beginning of its establishment, Mindray started from county-level hospitals and avoided the confrontation with international brands in the top three hospitals. Since then, with the steady improvement of Mindray's R&D strength and product quality, the company has entered the fast lane and listed on the New York Stock Exchange in 2006 after 15 years of establishment, becoming the first medical equipment company listed overseas in China. . In 2014, Mindray’s sales reached 8.19 billion yuan, and the compound growth rate from 2008 to 2014 was 24%. In 2015, Mindray, which has been in the US stock market for nearly 10 years, launched the privatization process. As of March 2016, Mindray announced that it has completed a $3.3 billion privatization transaction. On April 14th, the author interviewed Mindui Chairman Li Xiting and President Cheng Minghe at Mindray Shenzhen Headquarters to explain the development of China's medical equipment and Mindray's next step. Breaking the long-term monopoly of foreign medical equipment In recent years, the global medical equipment market has shown rapid growth. According to statistics released by the European Union's Medical Equipment Committee, the total global medical equipment market sales have risen rapidly from US$210 billion in 2002 to US$462.8 billion in 2013. The medical device market will continue to grow as the economy recovers and consumer demand for healthcare services grows in middle-income countries in emerging markets. In the domestic market, according to the National Bureau of Statistics of China, from 2001 to 2013, the total sales volume of China's medical equipment market increased from 17.9 billion yuan to about 188.9 billion yuan. That is to say, in spite of the impact of price factors, the total sales of medical equipment in China has increased by nearly 11.8 times in 13 years. With the aging of the population, the deepening of medical reform, and the state's support for the development of domestic medical equipment companies, it can be said that the potential of China's medical equipment market is still huge. Mindray, headquartered in Shenzhen, now has subsidiaries in more than 30 countries including Europe, North America, Latin America, Asia and Africa, and 32 branches in China. According to reports, Mindray's products and solutions have been applied to more than 190 countries around the world. In China, nearly 110,000 medical and health institutions and more than 95% of the top three hospitals have selected Mindray's products. "Miri's 25 years has witnessed the ever-evolving development path of China's medical equipment industry." - Li Xiting, Chairman of Mindray, China Economic Weekly, Chief Photographer of the Visual Center, Xiao Wei Minxi Chairman Li Xiting told the author that Mindray’s 25 years can be said to have witnessed the development path of China’s medical equipment industry from small to large, products from simplification to diversification, and technology upgrading. Today, Mindray’s products are not only domestic but also in Europe and America. The market also has a place, and has won many domestic markets, breaking the long-term monopoly of international manufacturers in China's medical equipment industry. Antineoplastic,Antineoplastic Agents,Natural Antineoplastic,Methotrexate Antineoplastic NOUVASANT GROUP LTD. , https://www.nouvasant.com
